Evidence map›Paper›PMID 29989463›Full record

ArticleClinical toxicology (Philadelphia, Pa.)2019

Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).

Amelia M Kasper, Alison D Ridpath, Roy R Gerona, Robert Cox, Robert Galli, Patrick B Kyle, Christina Parker, Justin K Arnold, Kevin Chatham-Stephens, Melissa A Morrison and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical toxicology (Philadelphia, Pa.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Amelia M Kaspera Epidemic Intelligence Service, Centers for Disease Control and Prevention , Atlanta , GA , USA.ORCID 0000-0001-7332-1890
Alison D Ridpathb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Roy R Geronac Department of Laboratory Medicine , University of California San Francisco , San Francisco , CA , USA.
Robert Coxd Mississippi Poison Center , Jackson , MS , USA.
Robert Gallie University of Mississippi Medical Center , Jackson , MS , USA.
Patrick B Kylee University of Mississippi Medical Center , Jackson , MS , USA.
Christina Parkerd Mississippi Poison Center , Jackson , MS , USA.
Justin K Arnoldb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Kevin Chatham-Stephensa Epidemic Intelligence Service, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Melissa A Morrisong Career Epidemiology Field Officer Program, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Olaniyi Olayinkaa Epidemic Intelligence Service, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Nykiconia Preacelyg Career Epidemiology Field Officer Program, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Stephanie M Kieszakb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Colleen Martinb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Joshua G Schierb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Amy Wolkinb Division of Environmental Hazards and Health Effects , National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Paul Byersi Mississippi State Department of Health , Jackson , MS , USA.
Thomas Dobbsi Mississippi State Department of Health , Jackson , MS , USA.
Centers for Disease Control and Prevention · USMississippi State Department of Health · USUniversity of Mississippi Medical Center · USWashington Poison Center · USUniversity of California, San Francisco · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

STUDY

objectivesIn April 2015, a multistate outbreak of illness linked to synthetic cannabinoid (SC) use was unprecedented in magnitude and severity. We identified Mississippi cases in near-real time, collected information on cases to characterize the outbreak, and identified the causative SC.

methodsA case was defined as any patient of a Mississippi healthcare facility who was suspected of SC use and presenting with ≥2 of the following symptoms: sweating, severe agitation, or psychosis during April 2-May 3, 2015. Clinicians reported cases to the Mississippi Poison Control Center (MPCC). We used MPCC data to identify cases at the University of Mississippi Medical Center (UMMC) to characterize in further detail, including demographics and clinical findings. Biologic samples were tested for known and unknown SCs by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF/MS).

resultsClinicians reported 721 cases (11 deaths) statewide; 119 (17%) were UMMC patients with detailed data for further analysis. Twelve (10%) were admitted to an intensive care unit and 2 (2%) died. Aggression (32%), hypertension (33%), and tachycardia (42%) were common. SCs were identified in serum from 39/56 patients (70%); 33/39 patients (85%) tested positive for MAB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) or its metabolites. Compared to all patients tested for SCs, those positive for MAB-CHMINACA were more likely to have altered mental status on examination (OR = 3.3, p = .05).

conclusionSC use can cause severe health effects. MAB-CHMINACA was the most commonly detected SC in this outbreak. As new SCs are created, new strategies to optimize surveillance and patient care are needed to address this evolving public health threat.

Indexed as

AdolescentAdultCannabinoidsCenters for Disease Control and Prevention, U.S.Disease OutbreaksFemaleHumansIllicit DrugsMaleMiddle AgedPoison Control CentersPublic HealthSubstance-Related DisordersSynthetic DrugsUnited StatesYoung AdultCannabinoidsIllicit DrugsSynthetic DrugsDrugs of abuseepidemiologyoutbreak investigationpoison centerssynthetic cannabinoids

Identifiers

PMID29989463
PMCPMC11331360
OpenAlexW2869712208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.